BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been assigned a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $133.1333.

Several research analysts recently weighed in on the stock. The Goldman Sachs Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday, March 11th. Truist Financial upgraded shares of BioNTech to a “strong-buy” rating in a research report on Wednesday, March 25th. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. TD Cowen decreased their price objective on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a research report on Wednesday, March 11th. Finally, Citigroup decreased their price objective on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Larson Financial Group LLC grew its holdings in shares of BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in shares of BioNTech by 0.6% in the fourth quarter. Kennedy Capital Management LLC now owns 21,065 shares of the company’s stock worth $2,005,000 after purchasing an additional 134 shares during the last quarter. Probity Advisors Inc. grew its holdings in shares of BioNTech by 5.7% in the third quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock worth $247,000 after purchasing an additional 135 shares during the last quarter. Mackenzie Financial Corp grew its holdings in shares of BioNTech by 4.0% in the third quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock worth $418,000 after purchasing an additional 165 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of BioNTech by 40.8% in the third quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock worth $77,000 after purchasing an additional 227 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Stock Up 1.1%

BNTX stock opened at $99.47 on Friday. The company has a current ratio of 7.54, a quick ratio of 7.49 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $98.18 and its 200 day moving average is $101.03. The stock has a market cap of $25.15 billion, a price-to-earnings ratio of -18.98 and a beta of 1.58. BioNTech has a 1-year low of $79.52 and a 1-year high of $124.00.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The company had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%. Sell-side analysts predict that BioNTech will post -3.88 EPS for the current fiscal year.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.